Pioneering the development of small molecule drugs that target various phases of cell cycle control
Who We Are
Cyclacel is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis biology. Our strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates that address oncology and hematology indications.
Our Core Values
Cyclacel retains virtually all marketing rights to our clinical-stage drug programs. To optimize our commercial return, we intend to enter into selected partnership arrangements and alliances in order to maximize available opportunities. Generally, we plan to develop compounds through proof-of-efficacy stage before seeking a partner.